Our newest case study, “Unlocking Science: Escaping the Data Velocity Trap,” walks through a real‑world composite of a precision oncology company that:
(1) Faced a 14‑week data backlog in an adaptive Phase II/III trial despite strong Breakthrough‑designated science.
(2) Brought in fractional interim clinical leadership with delegated authority over the incumbent CRO, data cleaning, and board communication.
(3) Cleared the backlog in 6 weeks, delivered a clean interim readout for the first 25 patients, and enabled a successful follow‑on raise that extended runway into 2026.
For VCs, growth equity, and crossover investors, the case is really about governance and capital protection. When and how should you deploy fractional CXO leadership instead of simply defaulting to a CEO swap or a big‑ticket consulting mandate.
If you’re a biotech venture capital investor overseeing a stressed portfolio company, or a biotech founder wrestling with an underperforming CRO, we have provided below the link to the full case study if you wish to dig into the operational details!